NSI-189 is a recently researched benzylpiperazine-aminopyridine; derived from pyrazine and nicotinamide. Randomised controlled trials have indicated that NSI-189 might be a promising candidate for neuronal cell production – also known as neurogenesis. Clinical trials are still undergo for this developmental drug for individuals with serious depressive disorders, post-traumatic stress disorder and age related diseases of the brain such as Alzheimer’s disease.
Important for Brain Functionality
NSI-189 is selective only to the hippocampus and the subventricular zones of the brain which makes it the ideal choice as a nootropic to improve cognitive function. So far, only self reported tests have been conducted on this nootropic (as a drug) and there are a significant lack of human trials which show evidence to support improvements in mental disease outcome but its potential ability to bind to glucocorticoid receptors could result in a decrease of cortisol. A decrease in cortisol is associated with improvements in the bodys ability to respond to stress, particulary in the brain and this can improve cognitive function. One other reason NSI-189 is showing promise is that it appears to stimulate neurogenesis in the hippocampus; this part of the brain is responsible for information from the short term memory and the long term memory. This is why the NSI-189 is considered to be a nootropic.
Vitamin B12 (cyanocobalamin) is an essential vitamin that is required for the development of red blood cells. It is also used to make the protective coating surrounding nerves; a vitamin particularly important for brain nerve cells.